Senior managers’ and Directors’ subscriptions in new issue

Many Directors and senior managers intend to participate in NeuroVive’s current
rights issue.
These commitments include the following:

  · Greg Batcheller, Chairman of the Board, has undertaken to subscribe for his
holding, corresponding to just over SEK 1,000,000.
  · By taking over subscription rights from Eskil Elmér, NeuroVive’s CEO Mikael
Brönnegård has undertaken to subscribe to a value of approx. SEK 200,000.
  · By taking over subscription rights from Eskil Elmér, Johannes Ehinger, a
NeuroVive researcher, has undertaken to subscribe to a value of approx. SEK
1,400,000.
  · Helmuth von Moltke and family, a Director, has undertaken to subscribe to a
value of approx. SEK 725,000.
  · Magnus Hansson, a NeuroVive researcher, has undertaken to subscribe for his
holding, and additional shares, corresponding to a value of approx. SEK 400,000.
  · Lennart Dreyer, a Director of NVP Asia Ltd, has undertaken to subscribe for
his holding, corresponding to approx. SEK 350,000.
  · Andreas Inghammar, co-founder, has undertaken to subscribe to a value of
approx. SEK 300,000.
  · By taking over subscription rights from Eskil Elmér, NeuroVive’s COO Jan
Nilsson has undertaken to subscribe to a value of approx. SEK 85,000.

NeuroVive’s current rights issue runs until 27 January 2014 inclusive, and is
open to current and new investors. More information about the share issue,
including videos of interviews and subscription applications, are available at
http://neurovive.irportalen.se/?lang=en

About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

Media and investor relations questions to:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.se
Please also use the above contact if you wish to arrange an interview with
NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 6220 (switchboard), Fax: +46 (0)46 888 8348
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this news release in accordance with the Swedish Securities Markets
Act. This information was provided to the media for publication at 15:50 CEST on
15 January 2014.